Abstract
Pleural mesothelioma is a relatively rare malignant tumor with generally persistent poor prognosis. The recent 2021 update of the World Health Organization (WHO) classification of tumors of the pleura and pericardium refined the nomenclature and adopted new molecular-genetic markers (breast cancer 1-associated protein 1 [BAP1], cyclin dependent kinase inhibitor 2A [CDKN2] etc.), which have diagnostic and prognostic significance.
Surgical treatment of pleural mesothelioma is strictly individualized and a lung-sparing procedure is preferred. ln addition to the platinum doublet with pemetrexed, the dual immunotherapy (nivolumab, ipilimumab) is available as first-line systemic treatment option. Wider use of immunotherapy and other experi mental treatment variants is currently the subject of clinical studies